Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Ciclopirox Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 289-C

    Initial Prior Authorization with Quantity Limit: Ciclopirox Topical Solution 8 Percent

    Customize your policy alerts

    Sign up for cvs_caremark Policy 289-C alerts

    Get alerted when Policy 289-C changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs initial prior authorization and quantity limits for ciclopirox topical solution 8% used to treat qualifying onychomycosis.

    Policy Summary
    PayerCVS Caremark
    PolicyCiclopirox topical solution 8% for qualifying onychomycosis
    Policy CodePolicy 289-C
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit documentation confirming dermatophyte-related onychomycosis, fungal diagnostic testing, and an inadequate response, intolerance, or contraindication to oral antifungal therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsDuration of approval
    6.6 mL/21 daysSingle-nail limit
    26.4 mL/21 daysMultiple-nail limit
    48 weeksSafety and efficacy limit

    Coverage Criteria

    Policy Summary
    PayerCVS Caremark
    PolicyCiclopirox topical solution 8% for qualifying onychomycosis
    Policy CodePolicy 289-C
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit documentation confirming dermatophyte-related onychomycosis, fungal diagnostic testing, and an inadequate response, intolerance, or contraindication to oral antifungal therapy.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and DocumentationClinical BackgroundInitial Onychomycosis AuthorizationStep Therapy RequirementsQuantity Limits

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Onychomycosis

    Authorization may be granted when ALL of the following criteria are met:

    Onychomycosis authorization

    • Diagnosis: The patient has onychomycosis of the nail due to dermatophytes.
    • Diagnostic confirmation: The patient's diagnosis has been confirmed with a fungal diagnostic test, such as a potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy.
    • Oral antifungal outcome or contraindication

      • Inadequate response: The patient has experienced an inadequate treatment response to an oral antifungal therapy.
      • Intolerance: The patient has experienced intolerance to an oral antifungal therapy.
      • Contraindication: The patient has a contraindication that would prohibit a trial of an oral antifungal therapy.
    • Administration restriction: The requested drug is not being used in a footbath.
    • Additional quantity support: If additional quantities are required, multiple nails are being treated.

      This condition applies only when additional quantities are requested.

    Use of the requested drug in a footbath is excluded from authorization.

    Provider Actions and Documentation

    Prior Authorization

    Clinical Authorization Criteria

    Prior authorization may be granted when the patient has onychomycosis of the nail due to dermatophytes and meets all required coverage criteria.

    • Diagnosis is confirmed by fungal diagnostic testing.
    • Patient meets an approved oral antifungal response, intolerance, or contraindication pathway.
    • The drug is not used in a footbath.
    • If additional quantities are requested, multiple nails are being treated.
    Step Therapy

    Oral Antifungal Trial or Exception

    Document that the patient has either failed, cannot tolerate, or cannot safely receive an oral antifungal therapy before requesting ciclopirox topical solution.

    • Inadequate treatment response to an oral antifungal therapy.
    • Intolerance to an oral antifungal therapy.
    • Contraindication prohibiting a trial of an oral antifungal therapy.
    Documentation Required

    Diagnostic Confirmation Required

    The patient's diagnosis must be documented as dermatophyte-related nail onychomycosis and confirmed with fungal diagnostic testing.

    • Acceptable testing includes potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy.
    • Include the diagnostic result and the associated diagnosis in the authorization documentation.
    Documentation Required

    Document Oral Antifungal History

    Provide the patient's oral antifungal treatment history or the clinical rationale for not conducting a trial.

    • Document inadequate response, intolerance, or contraindication to terbinafine, itraconazole, or another oral antifungal therapy.
    • Identify the relevant therapy and describe the response, adverse effect, or contraindication.
    Billing Rule

    Support Multiple-Nail Quantities

    When requesting quantities above the single-nail limit, document that multiple nails are being treated.

    • Single-nail treatment: 6.6 mL per 21 days or 19.8 mL per 63 days.
    • Multiple-nail treatment: 26.4 mL per 21 days or 79.2 mL per 63 days.
    • The 21-day duration applies to a 28-day fill period; 63 days applies to an 84-day fill period to allow time for refill processing.
    Denial Risk

    Failure to Meet Clinical Criteria

    Coverage may be denied when the request does not establish the required diagnosis, fungal testing, or oral antifungal treatment history.

    • Dermatophyte-related nail onychomycosis is not documented.
    • Fungal diagnostic testing is absent or does not confirm the diagnosis.
    • No inadequate response, intolerance, or contraindication to oral antifungal therapy is documented.
    • The requested drug is being used in a footbath.
    Denial Risk

    Excess or Unsupported Quantity

    Additional or excessive quantities may be denied unless the request is supported by documentation that multiple nails are being treated and remains within the applicable quantity limit.

    • Do not exceed 6.6 mL per 21 days or 19.8 mL per 63 days for treatment of a single nail without supporting multiple-nail documentation.
    • For multiple nails, do not exceed 26.4 mL per 21 days or 79.2 mL per 63 days.
    • Unsupported additional quantities or quantities exceeding the applicable limit are subject to denial.

    Clinical Background

    Ciclopirox topical solution 8% nail lacquer is indicated as topical treatment, as part of a comprehensive management program, for mild to moderate onychomycosis of the fingernails and toenails without lunula involvement due to Trichophyton rubrum in immunocompetent patients. The management program includes periodic removal of unattached infected nails by a qualified healthcare professional. Safety and effectiveness have not been established for daily use beyond 48 weeks, and concomitant use with systemic antifungal agents for onychomycosis is not recommended.

    Initial Onychomycosis Authorization

    Initial onychomycosis authorization

    Authorization may be granted when ALL of the following criteria are met:

    Initial ciclopirox therapy

    • Confirmed dermatophyte onychomycosis: The patient has onychomycosis of the nail due to dermatophytes confirmed by a fungal diagnostic test, such as a potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy.
    • Oral antifungal outcome or contraindication

      • Inadequate response: The patient has experienced an inadequate treatment response to an oral antifungal therapy.
      • Intolerance: The patient has experienced intolerance to an oral antifungal therapy.
      • Contraindication: The patient has a contraindication that would prohibit a trial of an oral antifungal therapy.
    • No footbath use: The requested drug is not being used in a footbath.
    • Multiple-nail support: If additional quantities are required, multiple nails are being treated.

      This condition applies only when additional quantities are requested.

    Step Therapy Requirements

    StepRequirementException
    1Trial of an oral antifungal therapyIntolerance or a contraindication that would prohibit the trial

    Quantity Limits

    Quantity Limits
    MedicationCiclopirox topical solution 8%
    TreatmentSingle nail
    Quantity limit6.6 mL per 21 days
    Quantity Limits
    MedicationCiclopirox topical solution 8%
    TreatmentSingle nail
    Quantity limit19.8 mL per 63 days
    Quantity Limits
    MedicationCiclopirox topical solution 8%
    TreatmentMultiple nails
    Quantity limit26.4 mL per 21 days
    Quantity Limits
    MedicationCiclopirox topical solution 8%
    TreatmentMultiple nails
    Quantity limit79.2 mL per 63 days